Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats

Cardiovascular Research

Volumn 43, Issue 2, 1999, Pages 389-397

  Ishiyama, Shigeru ^a   Hiroe, Michiaki ^b   Nishikawa, Toshio ^a   Shimojo, Takashi ^b   Hosokawa, Tetsumi ^c   Ikeda, Ikuo ^a   Toyozaki, Tetsuya ^d   Kasajima, Takeshi ^a   Marumo, Fumiaki ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

Inducible nitric oxide synthase; Myocarditis; Nitric oxide; Proinflammatory cytokines; Vesnarinone

Indexed keywords

CREATINE KINASE MB; CYCLIC GMP; CYTOKINE; INOTROPIC AGENT; INTERLEUKIN 1BETA; MYOSIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PIPERANOMETOZINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEMODYNAMIC MONITORING; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INOTROPISM; MACROPHAGE; MYOCARDITIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BLOTTING, NORTHERN; FEMALE; INTERLEUKIN-1; MYOCARDITIS; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; QUINOLINES; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033179382     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00105-4     Document Type: Article

References (29)

1. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increasing circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
2. Matsumori A. Animal models: Pathological findings and therapeutic considerations. Banatvala J.E. Viral infection of the heart. 1993;110-137 Edward Arnold, Kent, UK.
3. Hagewisch S., Web H.J., Hossfeld D.K. TNF-induced cardiomyopathy. Lancet. 333:1990;294-295.
4. Kitakaze M., Minamino T., Funaya H. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. Circulation. 95:1997;2108-2114.
5. Levine B., Kalman J., Myer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in on severe congestive heart failure. New Eng J Med. 323:1990;236-241.
6. Hosenpud J.D. The effects of interleukin 1 on myocardial function and metabolism. Clin Immunol Immunopathol. 68:1993;175-180.
7. Kelly R.A., Smith T.W. Cytokines and cardiac contactile function. Circulation. 95:1997;778-781.
8. McGowan F.X., Takeuchi K., delNido P.J., et al. Myocardial effects of interleukin-1. Transplant Proceed. 26:1994;209-210.
9. Balligand J.-L., Kelly R.A., Marsden P.A., Smith T.W., Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 90:1993;347-351.
10. A placebo-controlled, randomized, double-blind study of OCP-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther. 4:1990;419-426.
11. Sasayama S. What do the new inotropic drugs have to offer? Cardiovasc Drugs Ther. 6:1992;15-18.
12. Feldman A.M., Bristow M.R., Parmley W.W., et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New Engl J Med. 329:1993;149-155.
13. Matsumori A., Shioi T., Yamada T., Matsui S., Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 89:1994;955-958.
14. Matsui S., Matsumori A., Matoba Y., Uchida A., Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest. 94:1994;1212-1217.
15. Hirozane T., Matsumori A., Furukawa Y., et al. Prolongation of murine cardiac allograft survival with vesnarinone. J Mol Cell Cardiol. 29:1997;67-76.
16. Matsui S., Matsumori A., Matoba Y., Uchidada A., Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent. Vesnarinone suppression of natural killer cell activity and tumor necrosis factor-α production. J. Clin. Invest. 94:1994;1212-1217.
17. Hattori Y., So S., Hattori S., Kasai K., Shimoda S.-I. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res. 30:1995;187-192.
18. Ishiyama S., Hiroe M., Nishikawa T., et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 95:1997;489-496.
19. Okura Y., Yamamoto T., Goto S., et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol. 29:1997;491-502.
20. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
21. Nathan C., Xie Q. Regulation of biosynthesis of nitric oxide. J Biol Chem. 269:1994;13725-13728.
22. Kodama M., Matsumoto Y., Fujiwara M. In vivo lymphocyte-meiated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation. 85:1992;1918-1926.
23. 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Circulation. 86:1992;1965-1972.
24. Miyamoto G., Sasabe H., Odomi M., Shimizu T. High-performance liquid chromatographic procesure for the determination of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]-2 (1H)-quinolinone, in human plasma and urine. J Chromatogr. 338:1985;450-455.
25. 15N] nitrate in biological fluids. Anal Biochem. 126:1982;131-138.
26. Ishiyama S., Hiroe M., Nishikawa T., et al. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats. J Immunol. 161:1998;4695-4701.
27. Feinberg A.P., Vogelstein B.A. Technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 132:1983;6-14.
28. Kurosaki K., Ikeda U., Maeda Y., et al. Effects of vesnarinone on nitric oxide synthesis in rat cardiac myocytes. Cardiovasc Res. 38:1998;192-197.
29. Chon J.C., Goldstein S.O., Greenberg B.H., et al. The vesnarinone trial investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. New Engl J Med. 339:1998;1810-1816.